Showing 4731-4740 of 10521 results for "".
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).
- SkinCeuticals, Aesthetics Biomedical Join Forces for Vivace Experience Featuring SkinCeuticals C E Ferulichttps://practicaldermatology.com/news/skinceuticals-aesthetics-biomedical-join-forces-for-vivace-experience-featuring-skinceuticals-c-e-ferulic/2460558/SkinCeuticals is teaming up Aesthetics Biomedical’s Vivace Fractional Micro Needle Radio Frequency Treatment to create the professional Vivace Experience featuring SkinCeuticals C E Ferulic MaryAnn Guerra, CEO & President of Aesthetics Biomedical states, "Aesth
- Clearasil Steps Up to End Bullying, Support Skin Positivityhttps://practicaldermatology.com/news/clearasil-steps-up-to-end-bullying-support-skin-positivity/2460543/Clearasil is donating $25,000 to STOMP Out Bullying for National Bullying Prevention Month. As part of the partnership, Clearasil is also using its national platform to further the reach and impact of STOMP Out Bullying's efforts by sharing toolkits and educational resources wi
- Dr. Rafael Sierra is Cynosure's Newest R&D Advisorhttps://practicaldermatology.com/news/dr-rafael-sierra-is-cynosures-newest-rd-advisor/2460533/Rafael Sierra, PhD is back at Cynosure. The former Chief Technology Officer is now an R&D Advisor. "Dr. Sierra's passion for the science behind medical aesthetics and inherent knowledge of its clinical application are unparalleled," says Todd
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- AmorePacific Launches New Woke Skincare Brandhttps://practicaldermatology.com/news/amorepacific-launches-new-woke-skincare-brand/2460503/South Korea’s Amorepacific is launching its newest vegan-friendly lifestyle brand: Enough Project. This new brand is vegan-friendly, involves no animal testing, and contains no animal ingredients. In addition, Enough
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are curr
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Researchers Explore Nitric Oxide to Slow Progression of COVID-19https://practicaldermatology.com/news/industry-responds-to-covid-19-researchers-call-for-exploration-of-nitric-oxide-to-slow-progression-of-covid-19/2460477/George Washington University (GW) researchers urge renewed research of nitric oxide treatment as a potential tool to fight SARS-CoV-2, the coronavirus that causes COVID-19, in a review published in the journal Nitric Oxide. The authors suggest that if nitric oxide's efficacy is illustrat
- Leo Pharma: FDA Accepts BLA for Tralokinumab for ADhttps://practicaldermatology.com/news/leo-pharma-fda-accepts-bla-for-tralokinumab-for-ad/2460462/The FDA has accepted the Biologics License Application (BLA) for Leo Pharma’s tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD), the company says. A taget action date has been set in the second quarter of 2021. Tralokinumab is a fully human mo